MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need.
MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need.